mRNA COVID-19 Vaccines for COVID-19

This trial tests two different mRNA COVID-19 vaccines, mRNA-1283 and mRNA-1273, to evaluate their ability to boost the immune system and ensure safety in the current COVID-19 environment. Participants will receive one shot of either vaccine, aiding researchers in assessing effectiveness against new virus variants. Individuals over 65 or those 12 and older with risk factors for severe COVID-19 may be suitable for this study. This research aims to enhance vaccine options for those at higher risk of severe COVID-19 outcomes. As a Phase 4 trial, it involves FDA-approved vaccines, confirming their proven effectiveness while exploring additional benefits for more patients.

The trial does not specify if you need to stop taking your current medications. However, if you are on systemic immunosuppressive treatment, you may need to stop, as it is not allowed within 180 days before the study or during participation.

Research has shown that both the mRNA-1273 and mRNA-1283 COVID-19 vaccines are generally safe. For mRNA-1273, studies have found common side effects such as pain at the injection site, headache, tiredness, and chills. These effects are usually mild and occur soon after vaccination. However, some reports have noted more serious side effects, like heart inflammation, mostly after the second dose.

For mRNA-1283, safety findings mirror those of mRNA-1273. Reports indicate that pain at the injection site and tiredness are the most common side effects, generally mild and self-resolving. So far, studies have not directly linked any serious side effects to mRNA-1283.

Researchers are excited about mRNA-1273 and mRNA-1283 because they represent a new wave of COVID-19 vaccines using mRNA technology, which has been pivotal in the rapid development and deployment of vaccines. Unlike traditional vaccines that may use inactivated viruses or viral proteins, these vaccines introduce a small piece of mRNA that instructs cells to produce a harmless part of the virus, triggering an immune response. This mechanism allows for quicker adaptation to new variants, offering the potential for more effective protection against emerging strains. Additionally, mRNA-1283 aims to improve stability and ease of storage, addressing logistical challenges seen with earlier vaccines.

Research has shown that the mRNA-1273 vaccine, one of the treatments in this trial, is highly effective, with a 94.1% success rate in preventing COVID-19 symptoms, including severe cases. Studies also confirm its effectiveness in real-world situations, with 87.4% effectiveness against COVID-19 infections. Meanwhile, early results for mRNA-1283, another treatment option in this trial, indicate it generates a strong immune response, particularly against variants like Omicron. Recent studies have shown promising results, with mRNA-1283 achieving its main goals. Both vaccines use mRNA technology, which helps the body learn to recognize and fight the virus effectively.⁶⁷⁸⁹¹⁰